

Emotra: Negotiations about research and technology collaborations

Emotra AB (“Emotra”) is presently negotiating about research collaborations on EDOR® Test with prominent university hospitals in several European countries. The goal of these collaborations is the use of EDOR to identify patients who run an increased risk of depression relapse, but other psychiatric indications are also on the table. One experience we have drawn from these negotiations is that this new indication area has opened doors and offered us new opportunities.

Given that depressed patients are a large patient category for which the healthcare sector lacks methods that can provide objective biological data, this area has sparked interest in a lot of researchers and clinics. This area is in focus at a lot of psychiatric and psychological research organisations. It is important to stress the fact that if you can prevent a depression relapse, you also reduce the risk of a future suicide.

Our discussions with research institutes, new clinics that the Company has been in touch with in connection with marketing efforts, and psychiatric hospitals that are presently evaluating EDOR in routine clinical use, point to a significantly increased need for a method like EDOR. Naturally, this would require that the higher relapse risk, which was identified in the hyporeactive patient group, is confirmed in further studies. The reason for this increased need is the fact that the risk of a relapse is a problem that practitioners face every day, and with a great deal of uncertainty. An objective test that can indicate an increased risk would help them offer depressed patients more adequate treatment, which in turn would lower the risk for new depressive episodes, as well as attempted and successful suicides. For the Company, such a scenario would bring a higher volume of EDOR testing.

Research on mental illness has made enormous progress in the last few years, leading to an increased understanding of what happens in the brain in connection with a depression, anxiety and a number of other psychiatric conditions. New discoveries indicate that long-term stress on the brain is an important factor and that hyporeactivity, which can be identified using EDOR Test, is directly connected to this process.

For further information about the Company, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.